Kala Pharmaceuticals (KALA) Acquires Combangio

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. SPCX
2. LEVI
3. SBUX
4. NVDA
5. GOOGL
6. AAPL
7. SPY
8. APLD
9. ORCL
10. USO

Go back to Kala Pharmaceuticals (KALA) Acquires Combangio

Kala Pharmaceuticals Acquires Combangio, Expanding its Pipeline with a Clinical-Stage Novel Biologic for the Treatment of Persistent Corneal Epithelial Defect (PCED) and other Rare Ocular Surface Dise

November 15, 2021 8:45 AM EST

-- KPI-012 is a novel secretome with a multifactorial mechanism of action for development in PCED and other orphan ocular surface diseases driven by impaired corneal healing --
-- KPI-012 demonstrated positive safety and efficacy results in PCED Phase 1b clinical trial --
-- Kala expects to initiate Phase 2/3 trial in 3Q 2022 --
--Mark S. Blumenkranz, M.D., Professor Emeritus in the Department of Ophthalmology at Stanford University, appointed to Kalas Board of Directors --
-- Management to host conference call at 10:30 a.m. ET today --

WATERTOWN, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kala... More